Kodiak Sciences Announces Second Quarter 2022 Financial Results and Recent Business HighlightsPRNewsWire • 08/09/22
Kodiak Sciences: All Eyes For A Sentiment Turnaround After Positive Beacon ResultsSeeking Alpha • 08/08/22
Kodiak Sciences Reports Positive Topline Results from BEACON Phase 3 Study of Tarcocimab Tedromer (KSI-301) in Patients with Retinal Vein OcclusionPRNewsWire • 08/08/22
Kodiak Sciences Completes Enrollment in GLOW Phase 3 Clinical Trial of Tarcocimab Tedromer (KSI-301) in Patients with Non-Proliferative Diabetic RetinopathyPRNewsWire • 08/05/22
Why Is Kodiak Sciences Inc. (KOD) Up 88.3% Since Last Earnings Report?Zacks Investment Research • 06/09/22
Grand Opening of Kodiak Sciences' Purpose-built Bioconjugation Facility to Support Potential Commercial Manufacture of KSI-301, an Antibody Biopolymer Conjugate for Retinal DiseasesPRNewsWire • 05/19/22
Kodiak Sciences Announces First Quarter 2022 Financial Results and Recent Business HighlightsPRNewsWire • 05/10/22
Kodiak Sciences Announces Presentation of KSI-301 Phase 2b/3 Study Data in wet AMD at Upcoming Research ConferencesPRNewsWire • 04/29/22
Why Is Kodiak Sciences Inc. (KOD) Down 12.7% Since Last Earnings Report?Zacks Investment Research • 03/31/22
Kodiak Sciences Announces Fourth Quarter and Full Year 2021 Financial Results and Recent Business HighlightsPRNewsWire • 03/01/22
Here's Why Kodiak Sciences Inc. (KOD) is Poised for a Turnaround After Losing 82.3% in 4 WeeksZacks Investment Research • 02/25/22
Palo Alto Is Leading the Nasdaq Higher, but 1 Biotech Is Getting Crushed WednesdayThe Motley Fool • 02/23/22
Kodiak Sciences stock loses more than three-quarters of its value after disappointing drug trial resultsMarket Watch • 02/23/22